{"entity":{"id":"nct04616443","kind":"trial","name":"OH2 Injection in Combination With HX008 for Melanoma.","aka":[],"tldr":"A phase 1/2 trial of Pucotenlimab in melanoma, run by Binhui Biopharmaceutical Co., Ltd., now recruiting.","summary":"OH2 Injection in Combination With HX008 for Melanoma. is a phase 1/2 interventional study registered as NCT04616443 by Binhui Biopharmaceutical Co., Ltd., with 60 participants planned, started 2020-12-01 and due to reach its primary completion in 2025-11-30. Interventions recorded: OH2 injection, HX008 injection. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04616443","url":"https://clinicaltrials.gov/study/NCT04616443"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["pucotenlimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04616443","phase":"1/2","setting":"Phase Ib Study of the Combination Use of Recombinant Human GM-CSF Type II Herpes Simplex Virus (OH2) Injection (Vero Cells) and HX008 Injection in the Treatment of Melanoma","sponsor":"Binhui Biopharmaceutical Co., Ltd.","enrolled":60,"outcomes":[]},"route":"/trials/nct04616443/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"pucotenlimab","kind":"drug","name":"Pucotenlimab","route":"/drugs/pucotenlimab/"}],"company":[{"id":"binhui-biopharmaceutical","kind":"company","name":"Binhui Biopharmaceutical","route":"/companies/binhui-biopharmaceutical/"}]}}